MARKET

FUSN

FUSN

Fusion Pharmaceuticals Inc.
NASDAQ

Real-time Quotes | Nasdaq Last Sale

13.13
-0.50
-3.67%
Closed 18:02 08/05 EDT
OPEN
13.87
PREV CLOSE
13.63
HIGH
13.98
LOW
13.13
VOLUME
47.33K
TURNOVER
--
52 WEEK HIGH
19.00
52 WEEK LOW
12.19
MARKET CAP
547.05M
P/E (TTM)
-22.9265
1D
5D
1M
3M
1Y
5Y

EPS

FUSN News

More
H1 2020 Canadian IPO - CSE leads in number of non-CPC/SPAC IPOs (88%), GFL IPO accounts 77% of IPO amount
H1 2020 Canadian IPO - CSE leads in number of non-CPC/SPAC IPOs (88%), GFL IPO accounts 77% of IPO amount
CNW Group · 07/14 13:30
e.l.f. Beauty, Akouos See Activist Actions
Barrons.com · 07/10 22:13
Fusion Pharmaceuticals Announces Pricing of Initial Public Offering
HAMILTON , ON and BOSTON , June 25, 2020 /CNW/ -- Fusion Pharmaceuticals Inc. (FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced the pricing of its initial public offe
CNW Group · 06/26 02:39

Industry

Biotechnology & Medical Research
+0.18%
Pharmaceuticals & Medical Research
+0.35%

Hot Stocks

Symbol
Price
%Change

About FUSN

Fusion Pharmaceuticals Inc. is a clinical-stage oncology company. The Company is focused on developing radiopharmaceuticals as precision medicines. The Company has developed its Targeted Alpha Therapies (TAT) platform together with its Fast-Clear linker technology. Its technology enables it to connect alpha particle emitting isotopes to antibodies and other targeting molecules in order to selectively deliver the alpha particle payloads to tumors. Its TAT platform is underpinned by its research and insights into the underlying biology of alpha emitting radiopharmaceuticals as well as its differentiated capabilities in target identification, candidate generation, manufacturing and supply chain and development of imaging diagnostics. The Company’s lead product candidate is FPI-1434, that utilizes Fast-Clear linker to connect a humanized monoclonal antibody that targets the insulin-like growth factor I receptor (IGF-1R) with alpha emitting isotope actinium-225.
More

Webull offers kinds of Fusion Pharmaceuticals Inc stock information, including NASDAQ:FUSN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, FUSN stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading FUSN stock methods without spending real money on the virtual paper trading platform.